Cannabis Linked to Lower Inflammatory Markers in Patients with HIV

For years, scientists have explored whether cannabis can influence inflammation and immune health. That question becomes especially important for people living with HIV, where chronic inflammation can persist even when antiviral treatment is working well. A 2026 study¹ published in Brain, Behavior, & Immunity – Health suggests cannabis use may be linked to measurable anti-inflammatory effects in people living with HIV, while showing little evidence of major immune suppression.

The findings add to a growing body of research examining cannabinoids beyond symptom management alone. Instead of focusing only on pain, appetite, or sleep, researchers are now investigating how cannabis may interact with the immune system itself. Let’s dive into the research and what it means for those living with HIV.

Why This Study Matters

Modern antiretroviral therapy has dramatically improved life expectancy for people living with HIV. However, many individuals still experience chronic low-grade inflammation, even when the virus is well controlled. Researchers believe this lingering inflammatory activity may contribute to cardiovascular disease, metabolic disorders, cognitive decline, and other long-term health complications.

Scientists are now studying how cannabinoids, such as THC and CBD, could affect immune activity in patients with HIV, as they are known to influence inflammatory signaling pathways. At the same time, cannabis research is complicated. Smoking cannabis exposes the body to combustion byproducts and oxidants that may increase inflammation in some tissues. This creates an important scientific question: Does cannabis ultimately reduce or increase inflammatory activity in humans? The study aimed to help answer that question by examining a large group of people living with HIV who use cannabis.

Cannabis Use Is Common Among People Living With HIV

Cannabis use is relatively common among people living with HIV for several reasons. Some individuals use it to help manage symptoms of HIV, such as chronic pain, nausea, appetite loss, anxiety, sleep disturbances, or medication side effects. Others use cannabis recreationally or as part of broader wellness routines.

Researchers have also noted that people living with HIV may seek alternatives to opioids or other medications that carry additional risks or unwanted side effects. Because of this, understanding how cannabis affects immune health in this population has important clinical implications. Despite widespread use, human research in this area remains surprisingly limited. Much of the earlier evidence came from laboratory studies, animal models, or small observational trials. This latest research stands out because of both its size and the depth of biological analysis involved.

What the Researchers Studied

The study included 1,895 people living with HIV who were receiving antiretroviral therapy. Researchers assessed cannabis use through participant self-reporting and confirmed exposure using plasma mass spectrometry, which measures chemical compounds in the blood.

To understand how cannabis might affect inflammation and immunity, the researchers examined several layers of biological activity. They analyzed more than 2,300 plasma proteins linked to inflammation and immune signaling. They also evaluated immune function by testing how immune cells responded when stimulated in laboratory conditions. In addition, the team performed extensive profiling of circulating immune cells. Importantly, the researchers also accounted for tobacco use, which can strongly affect inflammatory markers and has complicated earlier cannabis studies.

What Multi-Omics Can Reveal

One of the most interesting aspects of the study was its use of “multi-omics” analysis. This approach combines multiple layers of biological data to create a broader picture of how the body is functioning. Instead of looking at only one inflammatory marker or one immune cell type, multi-omics can evaluate proteins, immune pathways, cellular behavior, and molecular interactions simultaneously.

This matters because the immune system is incredibly complex. A single biomarker rarely tells the whole story. By analyzing thousands of proteins and immune responses together, researchers can identify broader patterns that might otherwise remain hidden. In this study, multi-omics helped researchers observe how cannabis use correlated with widespread changes in inflammatory proteins rather than isolated immune effects. That kind of systems-level approach is becoming increasingly valuable in cannabis science, especially when studying conditions involving chronic inflammation.

How Cannabis May Affect Immune and Inflammatory Signaling

The researchers found that cannabis use was associated with 15 increased plasma proteins and 50 decreased plasma proteins. Many of the downregulated proteins were involved in inflammatory and immune-related pathways that help dictate how immune cells identify and respond to threats in the body. The findings suggest cannabis use may dampen certain inflammatory signaling processes at the systemic level.

Interestingly, the study did not find widespread suppression of immune cell function. Most cytokine production responses remained similar between cannabis users and non-users. The study also found relatively limited differences in circulating immune cell populations. Cannabis use was associated with increased numbers of CD27+CD21- B-cells but otherwise showed minimal changes in immune cell phenotypes.

Taken together, the results suggest cannabis reduces excessive inflammation without broadly weakening immune defenses, which is considered a major goal in many areas of medical research.

What This Does Not Prove

Although the findings are compelling, the study does not prove that cannabis directly causes improved immune health or better clinical outcomes in people living with HIV. The research was cross-sectional, meaning it captured a snapshot in time rather than following participants over many years. Because of this, researchers cannot determine cause and effect. Other lifestyle factors may also influence the results. Cannabis users and non-users may differ in diet, stress levels, sleep quality, medication adherence, exercise habits, or other variables that affect inflammation.

The study also did not establish which forms of cannabis participants used, how often they consumed it, or what cannabinoid concentrations were involved. Smoking, vaping, edibles, tinctures, and high-CBD products may all produce different biological effects.

Additionally, while reduced inflammatory protein activity may sound positive, inflammation itself is not always harmful. The immune system relies on inflammatory signaling to fight infections and maintain balance. Researchers still need to determine whether these observed changes translate into meaningful health benefits or risks over time.

Why More Clinical Research Is Needed

The study highlights how much scientists still have to learn about cannabis and immune regulation. Future clinical trials could help determine whether certain cannabinoids may reduce harmful chronic inflammation without impairing protective immune responses. Researchers also need to investigate dose, frequency, product composition, and delivery method.

Long-term studies will be especially important for understanding whether these molecular changes influence real-world outcomes such as cardiovascular health, neuroinflammation, metabolic disease, or quality of life in people living with HIV. There is also growing interest in whether cannabinoid-based therapies could eventually complement existing treatments for inflammatory conditions beyond HIV. However, rigorous clinical research remains essential. Cannabis contains hundreds of biologically active compounds, and its effects can vary dramatically depending on formulation and individual physiology.

As cannabis legalization expands globally, researchers are gaining more opportunities to study these questions in larger and more diverse populations.

The Bottom Line

This multi-omics study suggests cannabis use in people living with HIV was associated with reduced levels of several inflammation-related proteins while showing limited measurable effects on overall immune function. The findings do not prove cannabis is a treatment for HIV or chronic inflammation, but they do support the growing idea that cannabinoids may interact with immune signaling in complex and potentially meaningful ways.

For people living with HIV, the research adds another layer to ongoing conversations about cannabis, wellness, inflammation, and long-term health. It also underscores the need for carefully designed clinical trials that move beyond assumptions and examine cannabis through a rigorous scientific lens.

As researchers continue exploring the relationship between cannabinoids and immune biology, studies like this may help shape a more nuanced understanding of cannabis as more than just a recreational substance, but as a biologically active plant with measurable effects throughout the body.

References:

^{1. Elise M.G. Meeder, Jiang Xun, Adriana Navas, Louise E. van Eekeren, Marc J.T. Blaauw, Albert Groenendijk, Wilhelm A.J.W. Vos, Leo A.B. Joosten, Mihai G. Netea, Quirijn de Mast, Willem L. Blok, Annelies Verbon, Marvin A.H. Berrevoets, Nadira Vadaq, Vasiliki Matzaraki, Cheng-Jian Xu, Arnt F.A. Schellekens, Andre J.A.M. van der Ven, Immunomodulatory effects of cannabis use: a multi-omics study in people living with HIV, Brain, Behavior, & Immunity – Health, 2026, 101260, ISSN 2666-3546, https://doi.org/10.1016/j.bbih.2026.101260}